Nurix Therapeutics, Inc. NRIX
NASDAQ
| 08/31/2026 | 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 549.81M | -89.54M | -87.17M | -78.22M | -86.42M |
| Total Depreciation and Amortization | 3.62M | 3.85M | 3.78M | 4.03M | 5.00M |
| Total Amortization of Deferred Charges | -- | -- | -- | 600.00K | -- |
| Total Other Non-Cash Items | 9.84M | 9.83M | 7.59M | 7.31M | 7.58M |
| Change in Net Operating Assets | 52.37M | -20.72M | 3.90M | -1.55M | 16.46M |
| Cash from Operations | 615.63M | -96.57M | -71.91M | -67.83M | -57.39M |
| Capital Expenditure | -1.39M | -1.94M | -1.05M | -5.13M | -2.71M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 32.97M | 94.93M | -122.78M | 5.48M | 53.19M |
| Cash from Investing | 31.58M | 93.00M | -123.83M | 346.00K | 50.48M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5.16M | 66.00K | 19.98M | 236.01M | 1.16M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 5.16M | 66.00K | 19.98M | 236.01M | 1.16M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 652.37M | -3.51M | -175.77M | 168.52M | -5.76M |